Cover Image
市場調查報告書

神經膠質衍生神經營養因子 (GDNF) :開發中產品分析

Glial-Derived Neurotrophic Factor (GDNF) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364834
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
神經膠質衍生神經營養因子 (GDNF) :開發中產品分析 Glial-Derived Neurotrophic Factor (GDNF) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 46 Pages
簡介

本報告提供以神經膠質衍生神經營養因子 (GDNF) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

神經膠質衍生神經營養因子 (GDNF)概要

治療藥的開發

神經膠質衍生神經營養因子 (GDNF):開發中的產品 - 各開發階段

神經膠質衍生神經營養因子 (GDNF):開發中的產品 - 各治療範圍

神經膠質衍生神經營養因子 (GDNF):開發中的產品 - 各適應症

神經膠質衍生神經營養因子 (GDNF):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

神經膠質衍生神經營養因子 (GDNF):企業開發中的產品

神經膠質衍生神經營養因子 (GDNF):大學/機關開發中的產品

神經膠質衍生神經營養因子 (GDNF):治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

神經膠質衍生神經營養因子 (GDNF)治療藥的開發企業

  • NsGene A/S
  • UniQure N.V.

藥物簡介

神經膠質衍生神經營養因子 (GDNF):暫停中的計劃

神經膠質衍生神經營養因子 (GDNF):主要消息與新聞稿

附錄

目錄
Product Code: GMDHC0064TDB

Summary

Global Markets Direct's, 'Glial-Derived Neurotrophic Factor (GDNF) - Pipeline Review, H1 2016', provides in depth analysis on Glial-Derived Neurotrophic Factor (GDNF) targeted pipeline therapeutics.

The report provides comprehensive information on the Glial-Derived Neurotrophic Factor (GDNF) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glial-Derived Neurotrophic Factor (GDNF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glial-Derived Neurotrophic Factor (GDNF)
  • The report reviews Glial-Derived Neurotrophic Factor (GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glial-Derived Neurotrophic Factor (GDNF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glial-Derived Neurotrophic Factor (GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glial-Derived Neurotrophic Factor (GDNF) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glial-Derived Neurotrophic Factor (GDNF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glial-Derived Neurotrophic Factor (GDNF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glial-Derived Neurotrophic Factor (GDNF) Overview
  • Therapeutics Development
    • Glial-Derived Neurotrophic Factor (GDNF) - Products under Development by Stage of Development
    • Glial-Derived Neurotrophic Factor (GDNF) - Products under Development by Therapy Area
    • Glial-Derived Neurotrophic Factor (GDNF) - Products under Development by Indication
  • Glial-Derived Neurotrophic Factor (GDNF) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Glial-Derived Neurotrophic Factor (GDNF) - Products under Development by Companies
  • Glial-Derived Neurotrophic Factor (GDNF) - Products under Development by Universities/Institutes
  • Glial-Derived Neurotrophic Factor (GDNF) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glial-Derived Neurotrophic Factor (GDNF) - Companies Involved in Therapeutics Development
    • NsGene A/S
    • UniQure N.V.
  • Glial-Derived Neurotrophic Factor (GDNF) - Drug Profiles
    • AMT-090 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LAUR-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NsG-0301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Activate GDNF for Brain Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • smilagenin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glial-Derived Neurotrophic Factor (GDNF) - Dormant Projects
  • Glial-Derived Neurotrophic Factor (GDNF) - Featured News & Press Releases
    • Nov 28, 2013: Clinical trial launched to treat Sanfilippo B syndrome using gene therapy
    • Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane
    • Feb 18, 2013: Phytopharm Announces Results From Parkinson's Disease Clinical Trial Of Cogane
    • Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis
    • Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson's Disease
    • Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis
    • Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study
    • Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis
    • Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status
    • Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease
    • Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane
    • Apr 20, 2009: Phytopharm Announces The Commencement Of Clinical Study of Cogane In Patients With Parkinson's Disease
    • Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane
    • Jun 05, 2007: Phytopharm plc Presents Cogane Data At '11th International Congress Of Parkinson's Disease And Movement Disorders'
    • Nov 30, 2005: Phytopharm Announes That The Preliminary Trial Results Are Expected In December 2005
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by NsGene A/S, H1 2016
  • Pipeline by UniQure N.V., H1 2016
  • Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top